US-based Corindus Vascular Robotics has secured the US Food and Drug Administration (FDA) 510(k) clearance to market its CorPath GRX robotic system.

The CorPath System has been developed to assist interventional cardiologists to perform percutaneous coronary intervention (PCI).

During robotic-assisted PCI, physicianscan  use joysticks and touchscreen controls sitting in a radiation-shielded workstation, the Interventional Cockpit, to robotically control guidewires and balloon / stent catheters during an intervention.

"This is a tremendous advancement in the technology platform that will greatly extend the clinical capability of the system."

A component of CorPath platform, the CorPath GRX has been upgraded with features such as the Active Guide Management enabling control of the guide catheter along with robotically controlling of the guidewire and balloon or stent catheter, with one-millimeter advancement, from the control console.

This precise positioning will enable adjustment of guide catheter position during PCI procedures and can also expand the usage of CorPath for more complex cases.

CorPath GRX has also been incorporated with a redesigned bedside unit featuring an extended reach arm and a touchscreen display to streamline workflow.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Corindus chief medical officer Aaron Grantham said: "The new features of the next generation CorPath System, particularly the addition of active guide catheter management, will allow physicians to increase the complexity of procedures performed robotically.

“This is a tremendous advancement in the technology platform that will greatly extend the clinical capability of the system."